Skip to content

AbCellera Biologics

US · ABCL #2215 by market cap Listed 2020
9.69 -0.78 -7.45%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:59

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 5 in the most recent period (2026/Q3).
  • Total institutional ownership fell 2.0 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
37.23% -1.96pp
Institutions
158 -5
As of
2026/Q3 vs. prior period

Holder types

Individual/Insider21.64%
Hedge Fund16.14%
Mutual Fund14.43%
Public Company5.29%
Private Company1.02%
Family Office/Trust0.20%
Government Pension Fund0.12%
Other41.14%

Top holders as of 2026-04-01

Carl Hansen 17.60% · 57.03M sh
Baker Bros. Advisors LP 10.19% · 33.01M sh
Capital Research 4.19% · 13.58M sh
Two Sigma Investments, LP 3.22% · 10.44M sh
Veronique Lecault 2.97% · 9.61M sh
The Toronto-Dominion Bank 2.85% · 9.22M sh
Bank of America Corporation 1.90% · 6.14M sh
BlackRock 1.75% · 5.66M sh
UBS Asset Management 1.34% · 4.33M sh
ArrowMark Colorado Holdings, LLC 1.27% · 4.11M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 45 buys · 4 sells

NameRoleStake
Carl Hansen CEO, President & Chairperson 17.60%
Veronique Lecault CTO & Director 2.97%
Michael Hayden Lead Independent Director 0.46%
Stephen Quake Independent Director 0.34%
Andrew Booth Chief Financial Officer 0.19%
John Montalbano Independent Director 0.08%
Tryn Stimart Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer 0.00%
Lynn Seely Independent Director --
Andrew Lo Former Independent Director --
Wen-Chaun Lo Former Independent Director --
Victor Sandor Independent Director --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-12 Carl Hansen CEO, President & Chairperson Other Disposition -125,000 --
2026-11-12 Andrew Booth Chief Financial Officer Open Market Acquisition +8,600 $11.33
2026-11-11 Carl Hansen CEO, President & Chairperson Open Market Acquisition +60,565 $11.54
2026-08-23 Michael Hayden Lead Independent Director Open Market Acquisition +53,613 $10.64
2026-08-17 John Montalbano Independent Director Open Market Acquisition +10,000 $11.03
2026-08-13 Andrew Booth Chief Financial Officer Private Acquisition +37,200 $10.32
2026-08-11 Michael Hayden Lead Independent Director Open Market Acquisition +46,387 $10.37
2026-08-10 Michael Hayden Lead Independent Director Other Disposition -50,000 --
2026-06-30 Lynn Seely Independent Director Other Derivative Acquisition +152,207 $7.85
2026-06-30 Victor Sandor Independent Director Other Derivative Acquisition +152,207 $7.85
2026-06-10 Stephen Quake Independent Director Other Derivative Acquisition +111,701 $5.27
2026-06-10 Michael Hayden Lead Independent Director Other Derivative Acquisition +111,701 $5.27
2026-06-10 John Montalbano Independent Director Other Derivative Acquisition +111,701 $5.27
2026-06-02 Andrew Booth Chief Financial Officer Derivative Exercise and Retained +250,000 $0.19
2026-05-13 John Montalbano Independent Director Open Market Acquisition +20,000 $4.77
2026-02-26 Carl Hansen CEO, President & Chairperson Open Market Acquisition +38,000 $3.44
2026-02-26 Andrew Booth Chief Financial Officer Open Market Acquisition +42,600 $3.42
2026-02-25 Carl Hansen CEO, President & Chairperson Open Market Acquisition +177,457 $3.27
2025-12-31 Carl Hansen CEO, President & Chairperson Other Derivative Acquisition +2,106,505 $3.42
2025-12-31 Tryn Stimart Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer Other Derivative Acquisition +539,265 $3.42

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:59:30 · For reference only, not investment advice and not tailored to your situation.

AbCellera Biologics discussion 0 comments

Add a comment